With the disclosure of the first quarterly report of listed companies, the positions of many well-known 10 billion private placement companies such as Gaoyi assets, Panjing investment and yuanlesheng have surfaced. From the exposed positions, the dilemma reversal opportunities of medicine, automobile, consumption and other sectors have attracted much attention.
Zhejiang Gongdong Medical Technology Co.Ltd(605369) recently disclosed the first quarterly report. As of the end of March this year, the list of the top ten circulating shareholders of Panjing investment’s new products was 568000 shares; The China EU medical and health mixed fund managed by the well-known public fund manager Glenn has increased its position by 1.774 million shares. At the same time, the products of private placement source Lesheng also appeared in the list of Zhejiang Gongdong Medical Technology Co.Ltd(605369) top ten circulating shareholders. The number of shares held at the end of the first quarter was 597000 shares, unchanged from that at the end of last year.
Zhejiang Gongdong Medical Technology Co.Ltd(605369) is a high-tech enterprise specializing in the R & D, production and sales of disposable medical consumables. In 2021, the net profit attributable to the parent company was 311 million yuan, with a year-on-year increase of 37.68%. In the first quarter of this year, the company achieved a revenue of 348 million yuan, a year-on-year increase of 32.71%; The net profit attributable to the parent company was 95 million yuan, with a year-on-year increase of 19.77%.
It is worth noting that not only the 10 billion private placement of pharmaceutical stocks, but also the private placement as a whole has been in the pharmaceutical sector for two consecutive months.
According to the monthly report of China Resources trust sunshine private equity bull index (crefi index), the three industries with the largest increase in positions of crefi index component funds in March were materials, pharmaceutical, biotechnology and Life Sciences, and semiconductor and semiconductor production equipment, with an increase of 0.56%, 0.47% and 0.42% respectively. In February, the industry with the largest increase in crefi index component fund positions was pharmaceutical, biotechnology and Life Sciences, with an increase of 2.21%.
Liu Xiaolong, founder of juming investment, said: “in the past, the pharmaceutical industry faced a severe situation of centralized procurement, but after transformation, when the profits bottomed out after a sharp decline, it has the opportunity of ‘reverse reversal + growth’. Specifically, from the perspective of the segment track, the innovative drug companies listed in the past three years, the companies of generic drug transformation and innovative drugs that have accumulated a lot of cash, and the pharmaceutical device enterprises with relatively low domestic business deserve attention.”
In addition to the pharmaceutical sector, the plight and reversal opportunities of automobile, consumption and other sectors have also attracted much attention.
For example, Zhejiang Sunrise Garment Group Co.Ltd(605138) the first quarterly report shows that as of the end of March, the list of the top ten circulating shareholders of the three new products managed by Zhuo Liwei, the manager of Gaoyi asset fund, has a total shareholding of 7.637 million shares Zhejiang Sunrise Garment Group Co.Ltd(605138) its main business is the production and sales of textile fabrics and garments. In 2021, affected by the epidemic and the sharp rise in raw materials, the company realized a net profit of 291 million yuan, a year-on-year decrease of 0.56%. However, the company’s performance in the first quarter was brilliant, and the net profit attributable to the parent increased by 43.41% year-on-year.
Chengdu Haoneng Technology Co.Ltd(603809) , whose performance in the fourth quarter of last year was affected by factors such as rising prices of raw materials and increased costs, was favored by Deng Xiaofeng. According to the latest data, Chengdu Haoneng Technology Co.Ltd(603809) first quarter performance increased by 23.61% year-on-year; As of the end of March, the products managed by Deng Xiaofeng held Chengdu Haoneng Technology Co.Ltd(603809) 5734000 shares, unchanged compared with the end of last year. In the first quarter, Chengdu Haoneng Technology Co.Ltd(603809) shares fell nearly 23%.
Danshui spring said: “At present, the portfolio mainly focuses on the dilemma reversal opportunities of outstanding industry leaders. These companies have the characteristics of low fundamentals and emotional aspects, and the upward space of stock prices is far greater than the downward space. Specifically, the low fundamentals mean that the company and its industry are under the downward pressure of the economy and are at the low level of the development cycle. The prosperity will enter the upward cycle in the next two years, and the corporate profits have the potential to rise. The low emotional aspect means that , investors’ expectations of the company are generally low, and the stock price performance lags behind the market, making the valuation at a relatively reasonable or low level. “
